These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 23199707)

  • 1. Expression of serum human epididymal secretory protein E4 at low grade and high grade serous carcinomas.
    Zhu YF; He LS; Zhang ZD; Huang QS
    Asian Pac J Trop Med; 2012 Dec; 5(12):925-30. PubMed ID: 23199707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of TP53 and AGR3 to distinguish ovarian high-grade serous carcinoma from low-grade serous carcinoma.
    Qiu C; Wang Y; Wang X; Zhang Q; Li Y; Xu Y; Jin C; Bu H; Zheng W; Yang X; Lu N; Kong B
    Int J Oncol; 2018 Jun; 52(6):2041-2050. PubMed ID: 29620196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small Foci of Serous Component as a Predictor of Recurrence and Prognosis for Stage IA Endometrial Carcinomas.
    Miyamoto M; Takano M; Tsuda H; Soyama H; Aoyama T; Ishibashi H; Kato K; Iwahashi H; Matuura H; Yoshikawa T; Suzuki A; Hirata J; Furuya K
    Oncology; 2017; 93(1):29-35. PubMed ID: 28259868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum HE4 as a useful biomarker in discriminating ovarian cancer from benign pelvic disease.
    Zheng H; Gao Y
    Int J Gynecol Cancer; 2012 Jul; 22(6):1000-5. PubMed ID: 22426406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer.
    Vallius T; Hynninen J; Auranen A; Carpén O; Matomäki J; Oksa S; Virtanen J; Grénman S
    Tumour Biol; 2014 Dec; 35(12):12389-95. PubMed ID: 25190018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovarian cancer patients.
    Steffensen KD; Waldstrøm M; Brandslund I; Jakobsen A
    Int J Gynecol Cancer; 2011 Aug; 21(6):1040-7. PubMed ID: 21738039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mammary serine protease inhibitor and CD138 immunohistochemical expression in ovarian serous and clear cell carcinomas.
    Hasby EA
    Tumour Biol; 2016 Apr; 37(4):4889-900. PubMed ID: 26526579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma].
    Wang MJ; Qi J; Wang H; Li XX; Wei BJ; Fu C; Gao J; Han BB
    Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):540-3. PubMed ID: 22093635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer.
    Salminen L; Nadeem N; Jain S; Grènman S; Carpén O; Hietanen S; Oksa S; Lamminmäki U; Pettersson K; Gidwani K; Huhtinen K; Hynninen J
    Gynecol Oncol; 2020 Mar; 156(3):689-694. PubMed ID: 31889528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis.
    Kadija S; Stefanovic A; Jeremic K; Radojevic MM; Nikolic L; Markovic I; Atanackovic J
    Int J Gynecol Cancer; 2012 Feb; 22(2):238-44. PubMed ID: 22214964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
    Shen Y; Li L
    Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses.
    Abdel-Azeez HA; Labib HA; Sharaf SM; Refai AN
    Asian Pac J Cancer Prev; 2010; 11(1):111-6. PubMed ID: 20593939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC).
    Feng Z; Wen H; Ju X; Bi R; Chen X; Yang W; Wu X
    J Ovarian Res; 2017 Jan; 10(1):7. PubMed ID: 28122595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-grade and high-grade serous Mullerian carcinoma: review and analysis of publicly available gene expression profiles.
    May T; Shoni M; Crum CP; Xian W; Vathipadiekal V; Birrer M; Rosen B; Tone A; Murphy KJ
    Gynecol Oncol; 2013 Mar; 128(3):488-92. PubMed ID: 23253401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
    Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
    Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance.
    Cobb LP; Sun CC; Iyer R; Nick AM; Fleming ND; Westin SN; Sood AK; Wong KK; Silva EG; Gershenson DM
    Gynecol Oncol; 2020 Sep; 158(3):653-658. PubMed ID: 32709538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
    Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
    J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantification of ER/PR expression in ovarian low-grade serous carcinoma.
    Escobar J; Klimowicz AC; Dean M; Chu P; Nation JG; Nelson GS; Ghatage P; Kalloger SE; Köbel M
    Gynecol Oncol; 2013 Feb; 128(2):371-6. PubMed ID: 23103384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer.
    Anderson KS; Wong J; Vitonis A; Crum CP; Sluss PM; Labaer J; Cramer D
    Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):859-68. PubMed ID: 20200435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic Performance of Serum Human Epididymis Protein 4 (HE4) for Prediction of Malignancy in Ovarian Masses.
    Dewan R; Dewan A; Jindal M; Bhardawaj M
    Asian Pac J Cancer Prev; 2019 Apr; 20(4):1103-1108. PubMed ID: 31030480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.